You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
啟明醫療-B(02500.HK)與以色列高科技公司成立合資公司 以引進Healium新一代去腎交感神經術(RDN)創新器械
格隆匯 06-30 19:57

格隆匯6月30日丨啟明醫療-B(02500.HK)發佈公吿,已與以色列高科技公司Healium Medical Ltd.成立合資公司Renaly Ltd,以引進Healium的新一代去腎交感神經術(RDN)創新器械,並將RDN產品在全球範圍內進行研發,生產及商業化。公司將會成為Renaly的控股股東。

高血壓是最常見的慢性病之一,在世界範圍內約有1/3的成年人口患有高血壓病,中國的高血壓患病人口已突破3.3億,居世界首位。已有臨牀研究表明,RDN療法在治療未控制或頑固性高血壓方面具有顯着的安全性和有效性。

Healium專注研發超聲能量的治療及影像能力,其獨有的雙模態超聲技術平台,在實施超聲能量消融時可以實現超聲影像的監控。實現精準高效消融的同時,顯着降低由於消融不可控帶來的各種諸如神經消融不充分或血管損傷等問題的發生,可促使治療結果可預測,手術過程簡化,最終提升消融手術的安全性和有效性。

通過本次合作,公司將切入高血壓介入治療領域,而高血壓與心臟瓣膜疾病的發生息息相關。董事會深信,本次合作將顯著拓展公司產品佈局,憑藉公司在結構性心臟病領域的研發、生產及商業化的優勢,與現有產品線形成強大的組合,為市場未滿足的臨牀需求提供更佳的治療選擇。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account